Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

NCT ID: NCT00418431

Last Updated: 2024-06-05

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2/PHASE3
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-04-30
• Study Completion Date: 2006-08-31

Brief Summary

Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed "idiopathic detachment of the macula" in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment.

The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.

Conditions

Central Serous Chorioretinopathy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Intravitreal injection of Bevacizumab

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Any visual acuity.
• Central serous chorioretinopathy

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Asociación para Evitar la Ceguera en México

OTHER

Sponsor Role: lead

Principal Investigators

Mitzy E Torres Soriano, MD

Role: PRINCIPAL_INVESTIGATOR

Asociación para Evitar la Ceguera en México

Locations

Asociacion para Evitar la Ceguera en Mexico

Mexico City, Mexico City, Mexico

Countries

Mexico

Other Identifiers

APEC-0016

Identifier Type: -

Identifier Source: org_study_id